Latest Pharma and Biotech News
Pharmaceutical
17 March 2025 Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again Commission (MAHA).
Today's issue
Refine Search
Biotechnology
Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints. 18 March 2025
Biotechnology
Shares of French late-stage clinical biotech firm Nanobiotix leapt 17.6% to 3.47 euros after it announced the execution of another disciplined step in its financial strategy through the amendment of its global licensing agreement with Johnson & Johnson subsidiary Janssen entered into in 2023 to develop its radioenhancer NBTXR3. 18 March 2025
Pharmaceutical
Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD). 18 March 2025
Pharmaceutical
Israeli-headquartered RedHill Biopharma today revealed its plan to submit a UK marketing authorization application (MAA) for Talicia (low-dose rifabutin-triple therapy) for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP). 18 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Pharmaceutical
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. 18 March 2025
Biotechnology
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
Biotechnology
US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. 18 March 2025
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Pharmaceutical
Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C). 18 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, ie, mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). 18 March 2025
Biotechnology
Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute leukemia (MPAL). 18 March 2025
Pharmaceutical
US biotech OPKO Health and Israeli firm Entera Bio ave entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic conditions, and fibrotic diseases. 18 March 2025
Generics
The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s Inlyta, reports The Pharma Letter’s local correspondent.
drug of the US Pfizer. 18 March 2025
Pharmaceutical
We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials. 18 March 2025
Pharmaceutical
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
Biotechnology
California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing. 17 March 2025
Biotechnology
Japanese drugmaker Otsuka Holdings’ subsidiary Taiho Pharmaceuticals is to buy Araris Biotech, a Swiss oncology firm developing antibody drug conjugates (ADCs). 17 March 2025
Biotechnology
Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr Mark Velleca as chairman of the board of directors. 17 March 2025
Pharmaceutical
Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again Commission (MAHA). 17 March 2025
All news
Biotechnology
Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints. 18 March 2025
Biotechnology
Shares of French late-stage clinical biotech firm Nanobiotix leapt 17.6% to 3.47 euros after it announced the execution of another disciplined step in its financial strategy through the amendment of its global licensing agreement with Johnson & Johnson subsidiary Janssen entered into in 2023 to develop its radioenhancer NBTXR3. 18 March 2025
Pharmaceutical
Privately-held Italian pharma company Italfarmaco and Slovenia-based Medis Therapeutics have announced an exclusive distribution agreement for givinostat, the former company’s drug for the treatment of Duchenne muscular dystrophy (DMD). 18 March 2025
Pharmaceutical
Israeli-headquartered RedHill Biopharma today revealed its plan to submit a UK marketing authorization application (MAA) for Talicia (low-dose rifabutin-triple therapy) for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP). 18 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Pharmaceutical
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. 18 March 2025
Biotechnology
Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm. 18 March 2025
Biotechnology
US biotech Incyte has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 inhibitor. 18 March 2025
Pharmaceutical
Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. 18 March 2025
Pharmaceutical
Scottish gut health specialist EnteroBiotix has announced positive initial results with EBX-102-02, its full-spectrum microbiome product, from the TrIuMPH Phase IIa trial in adults with irritable bowel syndrome with constipation (IBS-C). 18 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, ie, mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). 18 March 2025
Biotechnology
Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute leukemia (MPAL). 18 March 2025
Pharmaceutical
US biotech OPKO Health and Israeli firm Entera Bio ave entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic conditions, and fibrotic diseases. 18 March 2025
Generics
The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s Inlyta, reports The Pharma Letter’s local correspondent.
drug of the US Pfizer. 18 March 2025
Pharmaceutical
We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials. 18 March 2025
Pharmaceutical
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
Biotechnology
California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing. 17 March 2025
Biotechnology
Japanese drugmaker Otsuka Holdings’ subsidiary Taiho Pharmaceuticals is to buy Araris Biotech, a Swiss oncology firm developing antibody drug conjugates (ADCs). 17 March 2025
Biotechnology
Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr Mark Velleca as chairman of the board of directors. 17 March 2025
Pharmaceutical
Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again Commission (MAHA). 17 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze